Výsledky vyhledávání - "Erika J. Lampert"

Akademický článek

Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses

Autor: Ashley Cimino-Mathews, Min-Jung Lee, Jung-Min Lee, Jane B Trepel, Akira Yuno, Erika J Lampert, Joo Sang Lee, Jayakumar Nair, Daniel An

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)

Background Preclinical data suggest cell cycle checkpoint blockade may induce an immunostimulatory tumor microenvironment. However, it remains elusive whether immunomodulation occurs in the clinical setting. To test this, we used blood and fresh tiss

Externí odkaz: https://doaj.org/article/37dcb1c5de0549a2b2645b4389d375f4

Zobrazit plný text záznamu

Supplementary Data from Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

Autor: Jung-Min Lee, Seth M. Steinberg, Janis M. Taube, Christina M. Annunziata, Stanley Lipkowitz, Marc R. Radke, Elliott Levy, Mohammad H. Bagheri, Erin Nichols, Andrew B. Nixon, James W. Hodge, Elizabeth M. Swisher, Yingmiao Liu, Jayakumar R. Nair, Ashley Cimino-Mathews, Michelle Padget, Alexandra Zimmer, Erika J. Lampert

Supplementary methods, tables, figures 1-5 with corresponding figure legends, and references

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3d4e53e79f70b59e1d9a2637b68d09a
https://doi.org/10.1158/1078-0432.22479107.v1

Zobrazit plný text záznamu

Data from Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

Purpose:Preclinical studies suggest PARP inhibition (PARPi) induces immunostimulatory micromilieu in ovarian cancer thus complementing activity of immune checkpoint blockade. We conducted a phase II trial of PARPi olaparib and anti–PD-L1 durvalumab

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::572309380d18f2e0fb8fb6a6ca8c8066
https://doi.org/10.1158/1078-0432.c.6530135

Zobrazit plný text záznamu

BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA-mutant ovarian cancer

Autor: Nitasha Gupta, Tzu-Ting Huang, Jayakumar R. Nair, Daniel An, Grant Zurcher, Erika J. Lampert, Ann McCoy, Ashley Cimino-Mathews, Elizabeth M. Swisher, Marc R. Radke, Christina M Lockwood, Jonathan B. Reichel, Chih-Yuan Chiang, Kelli M. Wilson, Ken Chih-Chien Cheng, Darryl Nousome, Jung-Min Lee

PARP inhibitors (PARPis) have changed the treatment paradigm inBRCA-mutant high-grade serous ovarian carcinoma (HGSC). However, most patients eventually develop resistance to PARPis, highlighting an unmet need for novel therapeutic strategies. Using

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f693361a258ac8c32a330772e35f83c0
https://doi.org/10.1101/2022.12.02.22283037

Zobrazit plný text záznamu

Akademický článek

Brain atrophy rates in first degree relatives at risk for Alzheimer's

Autor: Erika J. Lampert, Kingshuk Roy Choudhury, Christopher A. Hostage, Bharath Rathakrishnan, Michael Weiner, Jeffrey R. Petrella, P. Murali Doraiswamy

Publikováno v: NeuroImage: Clinical, Vol 6, Iss C, Pp 340-346 (2014)

A positive family history (FH) raises the risk for late-onset Alzheimer's disease though, other than the known risk conferred by apolipoprotein ε4 (ApoE4), much of the genetic variance remains unexplained. We examined the effect of family history on

Externí odkaz: https://doaj.org/article/8e37b1f9ab9e4a169385e93283885eb4

Zobrazit plný text záznamu

Efficacy and toxicity of carboplatin and gemcitabine administered on day 1 and day 8 (day1&8) versus day 1-only for platinum-sensitive recurrent epithelial ovarian cancer

Autor: Erika J Lampert, Peter G Rose, Meng Yao, Robert DeBernardo, Roberto J Vargas, Chad M Michener, Laura M Chambers

Publikováno v: International Journal of Gynecologic Cancer. :ijgc-2022

ObjectiveTo compare response rate, progression-free survival, overall survival, and toxicity of carboplatin and gemcitabine administered on day 1 and day 8 (day1&8) versus a modified day 1-only regimen in recurrent platinum-sensitive ovarian cancer.M

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b9ebafa83e6301301cc6b8762317cc97
https://doi.org/10.1136/ijgc-2022-004199

Zobrazit plný text záznamu

Long-term pelvic organ prolapse recurrence and mesh exposure following sacrocolpopexy

Autor: Tonya N Thomas, Marie Fidela R. Paraiso, Cecile A. Ferrando, Emily R W Davidson, Erika J. Lampert

Publikováno v: International Urogynecology Journal. 31:1763-1770

Large, long-term studies are needed to compare pelvic organ prolapse (POP) recurrence and mesh exposure following all modes of sacrocolpopexy (open, robotic, and laparoscopic). We hypothesized that the prevalence of recurrent POP and mesh exposure do

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecb19271f5504f6cc4ee98e2552cbf84
https://doi.org/10.1007/s00192-020-04291-8

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání